1Lipinski CA. Drug-like properties and the causes of poor solubili- ty and poor permeability [ J ]. J Pharmacol Toxicol Methods, 2000, 44( 1 ) :235-249.
2Amidon GL, Lennerns H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability [ J ]. Pharm Res, 1995, 12(3):413-420.
3Serajuddin AT. Salt formation to improve drug solubility[ J]. Adv Drug Deliv Rev, 2007, 59(7) :603-616.
4Stella V J, Nti-Addae KW. Prodrug strategies to overcome poor water solubility [ J ]. Adv Drug Deliv Rev, 2007, 59 ( 7 ) : 677- 694.
5Pouton CW, Porter CJH. Formulation of lipid-based delivery sys- tems for oral administration: materials, methods and strategies [J]. Adv Drug Deliv Rev, 2008, 60(6) :625-637.
6Parveen S, Misra R, Sanjeeb K, et al. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging [ J ]. Nanomed Nanotechnol Biol Med, 2012, 8 ( 2 ) : 147 -166.
7Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegrad- able polymeric nanopartieles as drug delivery devices[ J]. J Con- trol Release, 2001, 70 ( 1/2) : 1-20.
8Liu HB, Farrell S, Uhrich K. Drug release characteristics of uni- molecular polymeric micelles [ J ]. J Control Release, 2000, 68 (2) :167-174.
9Seholes PD, Coombes AGA, IIIum L, et al. The preparation of sub-500nm poly (lactic acid) nanopartieles prepared by double emulsion methods[ J]. J Control Release, 1993, 25:145-153.
10Song CX, l.abhasetwar V, Murphy H, et al. Formulation and characterization of biodegradable nanoparticles for intravaacular local drug delivery[J]. J Control Release, 1997, 43(2/3) :197-212.
